Drug survival, effectiveness, and safety of brodalumab for moderate‐to‐severe psoriasis over up to 3 years

Abstract

AbstractBackgroundBrodalumab is a monoclonal antibody and IL‐17 RA inhibitor that is approved for the treatment of moderate‐to‐severe psoriasis. The present study aims to estimate the drug survival (DS), effectiveness, and safety of brodalumab over a period of 156 weeks.MethodsThe primary objectives were: (i) to determine the treatment response rate at Weeks 16, 28, 52, 78, 104, and 156 as defined by PASI100, PASI90, and an absolute PASI ≤ 3 and (ii) long‐term DS. Secondary objectives included the evaluation of possible predictive factors associated with the achievement of response outcomes, and possible predictive factors associated with lower DS.ResultsThe treatment response was rapid, with 80.3% of patients achieving PASI ≤ 3, 66% PASI90, and 54.3% the complete clearance of disease at Week 16. The response improved at Week 28, when a plateau was achieved with mild loss of response at later time points, in particular for PASI100 and PASI90 in 55.2 and 65.5% of patients, respectively, at Week 156. After 156 weeks of treatment, 66.22% of patients were still on therapy, and the previous use of IL‐17 inhibitors appeared to be associated with an increased risk of treatment discontinuation (HR: 2.51, CI: 1.06–5.98, P = 0.037), and achievement of PASI ≤ 3 until Week 16 with less risk (HR: 0.27 CI: 0.14–0.51, P < 0.001). Bio‐naïve status was favorably associated with treatment response, while high BMI negatively affected the achievement of outcomes.ConclusionOur study confirms the good effectiveness and favorable safety profile of brodalumab in a real‐world setting over up to 3 years of treatment.